JS001 in Combination With RC48-ADC in Treatment of HER2-Positive Advanced Malignant Solid Tumors

NCT04280341 | Unknown Phase 1 DMC

• 1 other identifier: RC48-C013
• Study Type: interventional
• Target: 50
• Locations: 1 country
• Sites: 1

Brief Summary

This is a non-randomized, open-label, single-arm, multicenter Phase I clinical trial which will evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of RC48-ADC in combinaton with Anti-PD1 Monoclonal Antibody in Treatment of HER2-Positive Advanced Malignant Solid Tumors.

Conditions

HER2-Positive Solid Tumors

Keywords

RC48-ADC; JS001; HER2 positive solid Tumor

Outcome Measures

Primary Outcomes (2)

• DLT(dose-limiting toxicity) or Maximal Tolerance Dose (MTD)

  Side effects of drug or treatment that are serious enough to prevent an increase in dose or level of that treatment. The MTD is defined as the previous dose level.

  28 days

• adverse events

  Safety of participants followed for the duration of hospital stay, an expected average of 1 week

  1 year

Secondary Outcomes (9)

• ORR

  From date of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months

• DOR

  From date of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months

• PFS

  up to 2 years

• OS

  up to 2 years

• ADA

  up to 2 years

Study Arms (1)

RC48-ADC in combinaton with Anti-PD1 Monoclonal Antibody

EXPERIMENTAL

RC48-ADC(Recombinant Humanized Anti-HER2 Monoclonal Antibody-MMAE Conjugate) JS001(Recombinant Humanized Anti-PD1 Monoclonal Antibody)

Biological: RC48-ADC in combinaton with JS001

Interventions

RC48-ADC in combinaton with JS001 BIOLOGICAL

The study has 2 parts which include dose escalation phase and dose extension phase. Dose escalation will use a 3+3 design and will enroll cohorts of 3-6 patients with HER2-Positive Advanced Malignant Solid Tumors sequentially at escalating doses of 2.0mg/kg and 2.5mg/kg to RC48-ADC and JS001 is fixed dose of 3.0mg/mg

RC48-ADC in combinaton with Anti-PD1 Monoclonal Antibody

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Willing to sign the informed consent form;
• ≥18 years old;
• Diagnosed histologically or cytologically with local advanced or metastatic HER2-positive malignant solid cancer( indicating that IHC result is 2+,3+or1+ ) and under one of following situations: standard treatment-refractory (disease progression or no response), treatment-resistant, unable to receive treatment, or the standard treatment is unavailable;
• Having measurable or evaluable lesions according to RECIST 1.1;
• Having an ECOG performance status score of 0 or 1;
• Echocardiographic LVEF (left ventricular ejection fraction) ≥ 50%.
• NYHA CLAS 0-1;
• Having sufficient bone marrow, liver and kidney functions (based on the normal value of the clinical trial site) within 7 days before erollment: Absolute neutrophil count (ANC) ≥ 1.5×109/L,Platelets ≥ 100×109/L, hemoglobin≥ 9.0 g/dL；Total serum bilirubin ≤ 1.5×upper limit of normal (ULN);Without liver metastasis, ALT, AST or ALP ≤ 2.5×ULN; With liver metastasis, ALT, AST or ALP ≤ 5×ULN;Serum creatinine clearance rate ≥ 60 mL/min(Cockcroft-Gault formula);INR International Normalized Ratio ≤ 1.5 × ULN, APTT ≤ 1.5 × ULN;
• With an expected survival of more than 3 months;
• Male or female patients of childbearing potential must agree to use effective methods of contraception (such as double-barrier contraceptive methods, condoms, oral or injectable contraceptives and intrauterine devices) during the study period and within 24 weeks after the last dosing;

You may not qualify if:

• Known active uncontrolled or symptomatic CNS metastases, as indicated by clinical symptoms, cerebral edema, spinal cord compression, carcinomatous meningitis, leptomeningeal disease and/or progressive growth. Patients with a history of CNS metastases or cord compression are eligible if they have been definitively treated and are clinically stable o before the first dose of RC48-ADC.
• Prior treatment with HER2 targeted therapy while LVEF decline \<45% or absolute value of LVEF decline \>15%；
• Participation in any other studies within 4 weeks before study entry and/or during participation in the active treatment phase of the trial.
• Radical operation within 3 weeks before study entry but not include diagnostic puncture or peripheral vascular assess replacement ;
• Radical radiation therapy within 3 months before study entry; Patient of Palliative radiotherapy is eligible into this study if \<30 % Radiation area of bone marrow;
• Patients who underwent checkpoint inhibitor or tumor vaccines include not limited PD-1、 PD-1、PD-L1、CTLA4、LAG3;
• Patient has had systemic steroid therapy (≥10 mg/day of prednisone or physiologic replacement doses of hydrocortisone, or its equivalent) or immunosuppressive medication within 14 days prior to the first dose of study.
• Live vaccines within 28 days prior to the first dose of study and during trial treatment.
• Patient has an active autoimmune disease or a documented history of autoimmune disease (but not limited In terstitial lung Disease, uveitis, SLE, etal). Patients with vitiligo or resolved childhood asthma/atopy would be exception to this rule. Patients that require inhaled steroids or local steroid injections would not be excluded from the study. Patients with vitiligo or psoriasis that is stable on hormone replacement will not be excluded from the study.
• Active and clinically significant bacterial, fungal or viral infection including hepatitis B (HBV), hepatitis C (HCV), known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness.
• Patients have uncontrollable systemic disease which including diabetes, hypertendion, pulmonary fibrosis, etal.
• The toxicity of previous anti-cancer therapy has not returned to 0 or 1 level as specified in CTCAE v4.0 (except for hair loss);
• Patient has a history of allogeneic HSCT or organ transplation before study entry;
• Patients with hypersensitivity or delayed hypersensitivity reactions to certain components of RC48-ADC or similar drugs;
• Patients with symptomatic include but not limited ascites or pleural effusion and mental disease.

Sponsors & Collaborators

• Peking University: lead
• RemeGen Co., Ltd.: collaborator

Study Sites (1)

Beijing Cancer Hospital

Beijing, Beijing Municipality, 100142, China

RECRUITING

Related Publications (1)

• Wang Y, Gong J, Wang A, Wei J, Peng Z, Wang X, Zhou J, Qi C, Liu D, Li J, Lu M, Lu Z, Cao Y, Yuan J, Zhang R, Fang J, Zhang X, Shen L. Disitamab vedotin (RC48) plus toripalimab for HER2-expressing advanced gastric or gastroesophageal junction and other solid tumours: a multicentre, open label, dose escalation and expansion phase 1 trial. EClinicalMedicine. 2024 Jan 5;68:102415. doi: 10.1016/j.eclinm.2023.102415. eCollection 2024 Feb.

  PMID: 38235421 DERIVED

Study Officials

• Lin Shen, professor

  Peking University

  PRINCIPAL INVESTIGATOR

Central Study Contacts

lin Shen, professor

CONTACT

86-10-88196561; linshenpku@163.com

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: MD，Professor,Chief of Department of GI Oncology,Peking University Cancer Hospital

Study Record Dates

• First Submitted: December 30, 2019
• First Posted: February 21, 2020
• Study Start: June 3, 2020
• Primary Completion: December 1, 2024
• Study Completion: December 1, 2024
• Last Updated: August 25, 2023

Record last verified: 2023-08

Locations

CN (1)